All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
6 matching companies
Alnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
Ionis describes a portfolio of RNA- and DNA-targeted medicines, with separate pipeline, medicines, clinical-trial, and scientific-publication resources. Product-specific mechanisms and development status should be checked against dated disclosures.
Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
Arrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform.
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Coverage expands from sourced records; this database does not claim all biopharma companies.
